Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs

Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs

Source: 
MedCity News
snippet: 

Rondo Therapeutics is developing bispecific antibody drugs capable of treating solid tumors, which have eluded this type of cancer therapy. Led by co-founders and Teneobio veterans Shelley Force Aldred and Nathan Trinklein, the biotech startup has emerged from stealth backed by a $67 million Series A round of funding.